Maxime Pesant
Vice-President, Finance @ GeneChem
Westmount, Canada
Maxime Pesant is a Series B investor at GeneChem in Westmount focused on Biotechnology and Therapeutics. M. Pesant joined the team subsequently to the closing of AgeChem. Previously, he worked for GeneChem as a consultant and spent two years at CDP Capital Technologies – Biotechnologies as a Junior Analyst. He also held positions of Financial Analyst for various small businesses. M. Pesant received a Bachelor in Business Administration from HECMontreal in 2004 and is a member of the Ordre des CPA du Québec. He is also a CFA charterholder.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Maxime Pesant invests in
Stages Maxime Pesant invests in
Countries Maxime Pesant invests in
Investment Focus
Industry
- Biotechnology 2 (67%)
- Therapeutics 1 (33%)
Stage
- Series B 2 (67%)
- Funding Round 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Oligon
|
Oligon company provides emerging biotechnology services developing a novel class of multimodal RNA therapeutics. They provide RNA oligonucleotide consultants, research associates, and research scientists. Their contact is done through phone and email. | $14M / Sep 23, 2025 | |
KisoJi Biotechnology
|
KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers. | $40.6M / Series B / Dec 02, 2024 | |
Feldan Therapeutics
|
Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle. | $21M / Series B / Sep 04, 2024 |
Co-Investors
About GeneChem
GeneChem fund and the changing landscape of the genomics industry, the principals set out to raise their second focused fund, GeneChem Therapeutics Venture Fund L.P.. With committed capital of $136.5 million, the Therapeutics Fund's objectives were to invest within the genomics industry but specifically in companies developing therapeutics forproliferative disorders including cancer, infectious diseases, inflammation and diabetes.
GeneChem Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Elizabeth Douville
General Partner
|
|||
|
Maxime Pesant
Vice-President, Finance
|
|||
Fabienne Perreau
Administrative Assistant
|
|||
Inès Holzbaur
General Partner
|
|||
John Clement
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Maxime Pesant invest in?
Maxime Pesant invests primarily in Biotechnology and Therapeutics startups, most often at Series B and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Maxime Pesant last invest?
The most recent investment recorded for Maxime Pesant closed in Sep 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
